Capricor Therapeutics reported total assets of $330.4 million as of September 30, 2026, a decrease from $355.9 million at year-end 2025. The company is currently managing regulatory reviews for its lead product candidate, Deramiocel, while navigating legal disputes with Nippon Shinyaku and Mesoblast International.
Capricor Therapeutics reported Q3 2026 financial results and provided a regulatory update on its BLA for Deramiocel in Duchenne muscular dystrophy, which has a PDUFA date of November 22, 2026. The company ended the quarter with approximately $199 million in cash and marketable securities. Management highlighted clinical data showing a 76% slowing of upper limb decline in patients who switched to Deramiocel during the HOPE-3 open-label extension.
Term
Q3 2026
“This quarter, we took important steps forward on both our regulatory filing and our launch readiness, submitting two-year HOPE-3 OLE data in a major amendment to our BLA while advancing our manufacturing and commercial preparations. In the OLE phase, patients who switched from placebo to Deramiocel saw their upper limb decline slow by 76% compared with their year on placebo, and this past weekend our HOPE-3 cardiac results received the AHA Outstanding Research Award in Pediatric Cardiology.”
Linda Marbán, Ph.D., Capricor’s Chief Executive Officer
“As Duchenne progresses, boys and young men lose the use of their arms and hands, and with it their independence, which is what Deramiocel is designed to slow. We appreciate the FDA’s engagement throughout this review and are encouraged by the Agency’s current focus on rare disease, including its recently launched Rare Disease Framework Initiative. As we approach our PDUFA date, we remain confident in the strength of our data. With our San Diego facility operational, we are prepared to move quickly to bring Deramiocel to patients, if approved.”
Linda Marbán, Ph.D., Capricor’s Chief Executive Officer